Yu Bai

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

M. Ahn, Dong-Wan Kim, J. Yang, 2016, Science Translational Medicine.

Are Capecitabine and the Active Metabolite 5-FU CNS Penetrable to Treat Breast Cancer Brain Metastasis?

Shaorong Li, Xiuhua Zhang, Ziqiang Cheng, 2015, Drug Metabolism and Disposition.

DMD061820 411..417

Shaorong Li, Xiuhua Zhang, Ziqiang Cheng, 2015 .

Abstract B42: ATM deficiency sensitizes gastric cancer cells to the PARP inhibitior olaparib

A. Lau, M. O’Connor, Wenxiang Cheng, 2009 .

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Jing Li, B. Davies, Q. Ji, 2013, Journal of Translational Medicine.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

Jing Li, B. Davies, Q. Ji, 2013, Journal of Translational Medicine.

EGFR G796D mutation mediates resistance to osimertinib

Z. Wang, Xuehua Zhu, Chunyan Wu, 2017, Oncotarget.

Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells.

Yongxing Wang, Zheng-chao Tu, Zhen Wang, 2023, Journal of medicinal chemistry.

EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third‐Generation EGFR Tyrosine Kinase Inhibitor Osimertinib

Yi-long Wu, Jin-Ji Yang, Z. Wang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.